Broker upgrade, page-7

Yes, but every deal done in the field is a deal less for Viralytics. And while Viralytics has a small but growing profile in Australia (market cap and otherwise) it is still tiny in global terms.

Let enough waves pass, and you'll be stuck out at sea if the swell turns.

Big pharma will ask you to do as many studies as you'll fund. Doesn't mean much, especially when they show that they are already paying $ for Phase 1 and early Phase 2 compounds.

There is probably enough data. The question is whether these guys can entice a deal to the table and then sign it.

I wish they have never had their 'transformational' capital raising: we would be less diluted, and have a management keener to make a deal.